Stormy Daniels’ lawyer: No­var­tis made $400K in 'sus­pi­cious' pay­ments to Trump at­tor­ney Michael Co­hen

Stormy Daniels’ at­tor­ney Michael Ave­nat­ti has out­lined a se­ries of “sus­pi­cious fi­nan­cial trans­ac­tions” in­volv­ing close to $400,000 in pay­ments No­var­tis made to the ac­count of Es­sen­tial Con­sul­tants, which was ear­li­er used by Don­ald Trump’s per­son­al at­tor­ney Michael Co­hen to pay $130,000 to the adult film ac­tress to keep her silent about al­le­ga­tions of an af­fair with the pres­i­dent.

Ac­cord­ing to the re­port, No­var­tis $NVS made four wire pay­ments of $99,980 each, just un­der the $100,000 mark, which Ave­nat­ti not­ed be­gan last fall and were wrapped in ear­ly Jan­u­ary of this year, just weeks be­fore soon-to-be CEO Vas Narasimhan met with Trump in Davos. [This sto­ry has been up­dat­ed with new in­for­ma­tion here: No­var­tis now says that it paid Co­hen’s com­pa­ny $1.2M]

A spokesper­son for No­var­tis re­spond­ed to a query I sent Tues­day night, say­ing: “Still chas­ing af­ter this – but want to clar­i­fy for your in­for­ma­tion that any agree­ments with Es­sen­tial Con­sul­tants were en­tered be­fore our cur­rent CEO tak­ing of­fice in Feb­ru­ary of this year and have ex­pired.” Lat­er, the phar­ma gi­ant tried to put some ad­di­tion­al dis­tance be­tween Narasimhan and the pay­ments, which they said in­volved “health­care pol­i­cy mat­ters.”

Who­ev­er drove the deal at No­var­tis, get­ting swept up in the Daniels scan­dal at the height of the me­dia tem­pest — days ahead of a ma­jor pol­i­cy ini­tia­tive on drug pric­ing by Trump — is ex­tra­or­di­nar­i­ly em­bar­rass­ing for the Swiss com­pa­ny, which still has plen­ty of ex­plain­ing to do.

The bomb­shell in the re­port spot­light­ed $500,000 paid by Russ­ian oli­garch Vik­tor Vek­sel­berg, with close ties to Rus­sia’s au­thor­i­tar­i­an leader Vladimir Putin, af­ter the elec­tion. Ac­cord­ing to Ave­nat­ti, that mon­ey could have been used to re­pay Co­hen for the hush mon­ey he paid Daniels. An­oth­er $200,000 came from AT&T, which has con­firmed the pay­ments to re­porters cov­er­ing the sto­ry, say­ing it paid for “in­sights in­to un­der­stand­ing the new ad­min­is­tra­tion.” Ko­rea Aero­space In­dus­tries paid $150,000.

“Mr.  Vek­sel­berg  and  his  cousin  Mr.  An­drew  In­trater  rout­ed  eight  pay­ments  to  Mr.  Co­hen  through  a  com­pa­ny  named  Colum­bus  No­va  LLC  (“Colum­bus”)  be­gin­ning  in  Jan­u­ary  2017  and  con­tin­u­ing  un­til  at  least  Au­gust  2017,” states Ave­nat­ti’s re­port.

“Al­so  in­clud­ed  in  these  sus­pi­cious  fi­nan­cial  trans­ac­tions  are  four  pay­ments  in  late  2017  and  ear­ly  2018  to­tal­ing  $399,920  made  by  glob­al  phar­ma­ceu­ti­cal  gi­ant  No­var­tis  di­rect­ly  to  Es­sen­tial  in  four  sep­a­rate  trans­ac­tions  of  $99,980  each  (just  be­low  $100,000).

“Fol­low­ing  these  pay­ments,  re­ports  sur­faced  that  Mr.  Trump  took  a din­ner  meet­ing  with the  in­com­ing  CEO  of  No­var­tis be­fore  Mr.  Trump’s  speech at  the  World  Eco­nom­ic  Fo­rum  in  Davos,  Switzer­land  in  late  Jan­u­ary  2018.”

Ave­nat­ti in­clud­ed a link to a Fier­cePhar­ma sto­ry on the group of ex­ec­u­tives meet­ing with Trump for din­ner in Davos.

Overnight, No­var­tis ex­ecs scram­bled to cir­cle the wag­ons around their CEO, con­firm­ing the pay­ments but in­sist­ing Narasimhan was nev­er in­volved in the “arrange­ment.” Their state­ment:

In Feb­ru­ary 2017, No­var­tis en­tered in­to a one year agree­ment with Es­sen­tial Con­sul­tants short­ly af­ter the elec­tion of Pres­i­dent Trump fo­cused on US health­care pol­i­cy mat­ters. The terms were con­sis­tent with the mar­ket. The agree­ment ex­pired in Feb­ru­ary 2018.

As al­ready stat­ed, the en­gage­ment of Es­sen­tial Con­sul­tants pre­dat­ed Vas Narasimhan be­com­ing No­var­tis CEO. Dr. Narasimhan had no in­volve­ment what­so­ev­er with this arrange­ment.

No­var­tis was con­tact­ed in No­vem­ber 2017 by lawyers from the Spe­cial Coun­sel’s of­fice re­gard­ing the com­pa­ny’s agree­ment with Es­sen­tial Con­sul­tants. No­var­tis co­op­er­at­ed ful­ly with the Spe­cial Coun­sel’s of­fice and pro­vid­ed all the in­for­ma­tion re­quest­ed. No­var­tis con­sid­ers this mat­ter closed as to it­self and is not aware of any out­stand­ing ques­tions re­gard­ing the agree­ment.

Vas Narasimhan may have been still the in­com­ing CEO at No­var­tis at that point in late Jan­u­ary, but he had di­rect­ed the de­vel­op­ment ef­fort at the phar­ma gi­ant for sev­er­al years and had been tapped for the CEO’s job months be­fore his meet­ing with Trump, along with a large group of ex­ec­u­tives. He took the CEO job at the be­gin­ning of Feb­ru­ary as CEO Joe Jimenez stepped down.

This al­so isn’t No­var­tis’ first in­volve­ment in a cor­rup­tion in­ves­ti­ga­tion. A lit­tle more than a month ago the com­pa­ny agreed to pay a fine of $25 mil­lion to the SEC af­ter com­pa­ny reps were ac­cused of of­fer­ing doc­tors in Chi­na lav­ish en­ter­tain­ment in ex­change for boost­ing the use of No­var­tis’ drugs.

No­var­tis and the phar­ma in­dus­try in gen­er­al have been step­ping up their pres­ence in Wash­ing­ton DC, in­ten­si­fy­ing lob­by­ing ef­forts as Trump and his top of­fi­cials in health­care fo­cus on a pledge to dra­mat­i­cal­ly low­er drug prices in the US. Trump is ex­pect­ed to give a speech on that very top­ic this Fri­day. I fol­lowed up with some more ques­tions for No­var­tis, but haven’t heard back.

Ave­nat­ti, mean­while, took to Twit­ter to call out all the com­pa­nies in­volved in con­tribut­ing to a “slush fund.”

https://twit­ter.com/MichaelAve­nat­ti/sta­tus/994156631440216069

Im­age: Michael Ave­nat­ti Shut­ter­stock

FDA chief Stephen Hahn on Capitol Hill earlier this week (Getty Images)

As FDA’s work­load buck­les un­der the strain, Trump again ac­cus­es the agency of a po­lit­i­cal hit job

Peter Marks appeared before a virtual SVB Leerink audience yesterday and said that his staff at FDA’s CBER is on the verge of working around the clock. Manufacturing inspections, policy work and sponsor communications have all been pushed down the to-do list so that they can be responsive to Covid-related interactions. And the agency’s objective right now? “To save as many lives as we can,” Marks said, likening the mortality on the current outbreak as equivalent to “a nuclear bomb on a small city.”

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

September 23, 2020 – Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain)  

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales 

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition

President Donald Trump reacts after signing an executive order following his remarks on his healthcare policies yesterday in Charlotte, North Carolina (Getty Images)

Op-ed: Will phar­ma re­al­ly pay for Trump’s lat­est law­less promise to 33 mil­lion Medicare ben­e­fi­cia­ries? Not like­ly

Sitting atop the executive branch, President Donald Trump is the ultimate authority at the FDA. He can fast track any vaccine to approval himself. If it came to that, of course.

What he can’t do is unilaterally order the legislative branch to loosen the Treasury’s coffers for $6.6 billion. Nor can he command pharmaceutical companies to pay for $200 vouchers sent to 33 million Medicare beneficiaries for prescription drugs before the election.

President Donald Trump and FDA Commissioner Stephen Hahn (AP Images)

FDA is­sues fi­nal rule al­low­ing im­por­ta­tion of drugs from Cana­da — but al­so keeps the pow­er to re­voke it

Just over a month away from the presidential election, the FDA has issued a final regulation fulfilling President Trump’s promise to let states import certain prescription drugs from Canada.

On Thursday, Trump told a crowd in North Carolina that the new rule goes into effect “today.” But the published regulation states that it won’t take effect for 60 days. And even then, it could be a while before cheaper drugs make it across the border.

The win­dow is wide open as four more biotechs join the go-go IPO class of 2020

It’s another day of hauling cash in the biopharma world as four more IPOs priced Friday and a fifth filed its initial paperwork.

The biggest offering comes from PMV Pharma, an oncology biotech focusing on p53 mutations, which raised $211.8 million after pricing shares at $18 apiece. Prelude Therapeutics, developing PRMT5 inhibitors for rare cancers, was next with a $158 million raise, pricing shares at $19 each. Graybug Vision raised $90 million after pricing at $16 per share for its wet AMD candidates, and breast cancer biotech Greenwich Lifesciences brought up the rear with a small, $7 million raise after pricing shares at $5.75.

J&J of­fers PhI/IIa da­ta show­ing its sin­gle-dose vac­cine can stir up suf­fi­cient im­mune re­sponse

Days after J&J dosed the first participants of its Phase III ENSEMBLE trial, the pharma giant has detailed the early-stage data that gave them confidence in a single-dose regimen.

Testing two dose levels either as a single dose or in a two-dose schedule spaced by 56 days in, the scientists from Janssen, the J&J subsidiary developing its vaccine, reported that the low dose induced a similar immune response as the high dose. The interim Phase I/IIa results were posted in a preprint on medRxiv.

Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Play-by-play of Gilead­'s $21B Im­munomedics buy­out de­tails a fren­zied push — and mints a new biotech bil­lion­aire

Immunomedics had not really been looking for a buyout when the year began. Excited by its BLA for Trodelvy, submitted to the FDA in late 2019, executive chairman Behzad Aghazadeh started off looking for potential licensing deals and zeroed in on four potential partners, including Gilead, following January’s JP Morgan Healthcare Conference in San Francisco. Such talks advanced throughout the year, with discussions advancing to the second round in mid-August.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,600+ biopharma pros reading Endpoints daily — and it's free.

New York governor Andrew Cuomo (AP Images)

An­drew Cuo­mo says New York will un­der­take its own vac­cine re­view process, and wouldn’t rec­om­mend trust­ing the fed­er­al gov­ern­ment

The concerns keep mounting over President Donald Trump’s politicization of the FDA and other federal agencies guiding the development of a safe and effective vaccine. And today, the telegenic New York governor Andrew Cuomo appeared to introduce even more politics into the matter — latest in an ongoing series of incidents that have cast the proudly independent FDA in starkly political terms.

During his daily press conference Cuomo said that the state will review any coronavirus vaccines approved by the federal government, citing a lack of trust in the Trump administration. The announcement comes one day after Trump accused the FDA of making an “extremely political” move in proposing stricter vaccine guidance.

President Trump walks past HHS secretary Alex Azar (Getty Images)

Azar falls in line un­der Trump again. Ex­perts say he's re­in­forc­ing a dark sig­nal sent to the FDA

In the latest incident where Alex Azar has steadfastly taken the side of President Donald Trump over that of the FDA, the HHS secretary was noncommittal this morning when asked if he supports the attempt by his subordinates at the FDA to strengthen guidelines for a vaccine EUA.

Appearing on NBC’s Today Show, the HHS secretary muddied the waters, stating that the guidance that matters is the one that is “actually already out there.”